

# Consolidated Results of Operations for the Fiscal Year Ended March 2025

May 15, 2025

Remixpoint is a company that **tackles, through business, issues that arise as society transforms**



Energy  
business



Resilience  
business



Medical  
business



Financial  
Investment  
Business

# Major businesses



## Energy business

### Electricity retailing business


- Supply high-voltage and low-voltage customers with electricity throughout Japan, excluding Okinawa area and isolated islands
- We offer multiple plans, including market-linked plans, to meet the diverse needs of consumers, achieving both business risk reduction and stable revenue assurance.



## Resilience business

### Renewable energy/energy-saving consulting and BCP response-related business

- Sales of the Company's original, hybrid-type home-use power storage system, "remixbattery"
- Sales of industrial-use lithium-ion, three-phase 200V hybrid power storage system



- Consulting on obtaining subsidies and other kinds of financial assistance



## Medical business

### Web marketing business for medical institution and Welfare business

- Web marketing support designed for sales support of medical institutions
- Management consulting specialized for dental and medical clinics, etc



## Financial Investment Business

Investment and financing business related to cryptocurrency investment, stock investment, and loans, etc.

## Consolidated Financial Results Forecast for Fiscal Year Ending March 31, 2026

For the fiscal year ending March 2026, each business segment is expected to outperform its performance in the fiscal year ended March 2025.

(Millions of yen)

		FY2024/25	Forecast for FY2025/26
<b>Net sales</b>	Energy business	20,663	22,905
	Resilience business	1,370	2,524
	Financial Investment Business	▲2,049	6,376 ~ 9,519
	Others	1,144	203
	<b>Total</b>	<b>21,129</b>	<b>32,010 ~ 35,153</b>
<b>Operating profit</b>	Energy business	1,394	1,851
	Resilience business	290	460
	Financial Investment Business	▲2,098	6,295 ~ 9,438
	Others	40	1
	Business segment adjustment	▲837	▲909
	<b>Total</b>	<b>▲1,211</b>	<b>7,698 ~ 10,841</b>
<b>Ordinary profit</b>		<b>▲541</b>	<b>7,698 ~ 10,841</b>
<b>Profit attributable to owners of parent</b>		<b>▲593</b>	<b>6,620 ~ 8,800</b>

※ Others include Medical business.

# Consolidated Financial Results Forecast for Fiscal Year Ending March 31, 2026 (Financial Investment Business)


The following are the estimated prices of crypto assets held as of April 1, 2025.  
The forecast is prepared based on the assumption that the following levels will be reached.

(US dollar)

Types of Crypto Assets	During the fiscal year ending March 31, 2026		
	Quantity (at beginning of period)	Low expected price	High expected price
<b>BTC</b>	616.00 BTC	150,000.00	180,000.00
<b>XRP</b>	1,191,204.80 XRP	3.30	4.30
<b>ETH</b>	901.45 ETH	3,250.00	4,300.00
<b>DOGE</b>	2,802,312.00 DOGE	0.30	0.43
<b>SOL</b>	13,920.07 SOL	250.00	300.00

## Sale of ZERO MEDICAL shares

On April 25, 2025, the Company resolved to transfer all of its holdings in ZERO MEDICAL, and expects to record an extraordinary gain in the first quarter of the fiscal year ending March 2026.



**To promote optimal allocation of management resources and restructuring of the business portfolio, we will concentrate management resources on major businesses to further enhance corporate value.**

# Fiscal Year Ended March 2025 Results Summary

# Results for the Fiscal Year Ended March 2025

Although sales increased year-on-year, Profits decreased due to the impact of a burden of capacity contributions that started in the current fiscal year and write-down of crypto assets in the financial investment business.


(Millions of yen)

		FY2023/24	FY2024/25
Net sales	Energy business	18,886	20,663
	Resilience business	1,219	1,370
	Financial Investment Business	—	▲2,049
	Medical business	278	1,144
	Others	102	—
	<b>Total</b>	<b>20,487</b>	<b>21,129</b>
Operating profit	Energy business	2,296	1,394
	Resilience business	131	290
	Financial Investment Business	—	▲2,098
	Medical business	▲7	43
	Others	24	▲3
	Business segment adjustment	▲701	▲837
	<b>Total</b>	<b>1,743</b>	<b>▲1,211</b>
Ordinary profit		1,758	▲541
Profit attributable to owners of parent		1,070	▲593




# Results for the Fiscal Year Ended March 2025

## Net sales



## Operating profit



## Topics

### Energy business

- The total contracted capacity of both high-voltage and low-voltage customers as well as net sales increased compared to the previous year as a result of efforts such as strengthening new sales activities and releasing a new plan tailored to customer needs.
- The amount of capacity contributions of approximately in FY2024/25, 1,479 million yen was recorded as a cost of sales, resulting in a year-on-year decrease in operating profit. For the fiscal year ending March 2026, segment profit is expected to recover since the total amount of capacity contributions is expected to decrease.

### Resilience business

- The development of sales agents for storage batteries and active promotion of sales activities led to a significant increase in the number of units sold of "remixbattery," resulting in increased net sales.

### Financial Investment Business

- We are driving the investment and lending activities throughout the group. In November 2024, we began to recognize the valuation gains and losses of our held cryptocurrencies as sales revenue.

# Quarterly statements of income

(Millions of yen)

		FY2023/24				FY2024/25			
		Apr-Jun (1Q)	Jul-Sep (2Q)	Oct-Dec (3Q)	Jan-Mar (4Q)	Apr-Jun (1Q)	Jul-Sep (2Q)	Oct-Dec (3Q)	Jan-Mar (4Q)
Net sales	Energy business	4,079	5,624	4,501	4,681	3,798	6,350	4,804	5,710
	Resilience business	122	226	278	591	193	271	329	575
	Financial Investment Business	—	—	—	—	—	—	84	▲2,134
	Medical business	—	—	—	278	315	339	301	188
	Others	101	1	—	—	—	—	—	—
	<b>Total</b>	<b>4,303</b>	<b>5,852</b>	<b>4,780</b>	<b>5,550</b>	<b>4,307</b>	<b>6,961</b>	<b>5,520</b>	<b>4,340</b>
Operating profit	Energy business	455	766	486	587	181	629	272	310
	Resilience business	▲20	35	34	82	▲2	31	44	217
	Financial Investment Business	—	—	—	—	—	—	67	▲2,166
	Medical business	—	—	—	▲7	49	56	20	▲82
	Others	4	1	20	▲1	▲0	▲0	▲0	▲1
	Business segment adjustment	▲199	▲175	▲139	▲187	▲174	▲218	▲178	▲265
	<b>Total</b>	<b>241</b>	<b>627</b>	<b>401</b>	<b>473</b>	<b>53</b>	<b>497</b>	<b>225</b>	<b>▲1,988</b>
Ordinary profit		213	615	465	463	41	467	951	▲2,001
Profit attributable to owners of parent		250	650	439	▲269	19	408	927	▲1,948

# Consolidated balance sheets

(Millions of yen)

		As of March 31, 2024	As of March 31, 2025
Assets	Cash and deposits	13,573	5,103
	Trade receivables and contract assets	3,554	3,766
	Merchandise	251	146
	Owned cryptoassets	68	8,674
	Operational investment securities	—	415
	Other	264	550
	Total current assets	17,714	18,657
	Total non-current assets	1,999	1,886
	Total assets	19,714	20,543
Liabilities	Accounts payable - trade	565	1,233
	Deposits received	97	223
	Income taxes payable	14	61
	Other	644	1,001
	Total current liabilities	1,322	2,519
	Total non-current liabilities	422	111
	Total liabilities	1,744	2,631
Net assets		17,969	17,911
Total liabilities and net assets		19,714	20,543

- ① Numerical forecasts and future outlooks presented or stated in this document are based on judgments, assessments, and assumptions made using information currently in the possession of the Remixpoint Group.  
Due to the uncertainties inherent in these judgments, assessments, and assumptions as well as future changes in business administration, internal/external circumstances, etc., the actual outcomes may be substantially different from the projections made. The Remixpoint Group provides no warranties as to the reliability of any representation related to future projections.
- ② This document is for the purpose of providing information, and in no way constitutes a solicitation by the Remixpoint Group to engage in any activity.
- ③ The citation or duplication of this document for any purpose without consent is prohibited.